<DOC>
	<DOCNO>NCT00160992</DOCNO>
	<brief_summary>Patients advance stage melanoma underwent vaccination Melan-A/MART-1 peptide display detectable level Melan-A specific CD8+ T cell peripheral blood eligible trial . After collect freeze tumor specific T cell via apheresis , patient undergo single cycle immunosuppressive chemotherapy . 3 day , cell reinfused peptide vaccination continue . The aim immunotherapy protocol boost tumor specific T cell immune recovery period order reinforce patient ' immune response tumor .</brief_summary>
	<brief_title>Adoptive Cell Transfer Combined With Peptide Vaccination Transiently Immunosuppressed Melanoma Patients</brief_title>
	<detailed_description>Patients previously vaccinate Melan-A/MART-1 peptide eligible . Whole PBMC 's contain Melan-A specific CD8+ lymphocytes collect via lymphocytapheresis freeze . Lymphodepleting chemotherapy consist 2 day Busulfan 2mg/kg day -7 , -6 , follow Fludarabine 30mg/m2 day -5 , -4 , -3 . At day 0 , whole untreated PBMC 's reinfused patient vaccination Melan-A analog peptide restart repeat every 4 week . Immunomonitoring detailed FACS analysis use tetramers perform day 0,8,15,30 , monthly . The aim boost Melan-A specific CD8 T cell vivo homeostatic proliferation lymphodepletion antigen drive proliferation due peptide vaccination .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Stage IV melanoma tumor express MelanA patient HLAA2 subtype Detectable immune response peptide vaccination MelanA Disease progression peptide vaccination Cerebral metastases rapidly progressive disease , necessitate systemic chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Adoptive cell transfer</keyword>
	<keyword>peptide vaccination</keyword>
	<keyword>melanoma</keyword>
	<keyword>immunosuppression homeostatic proliferation</keyword>
</DOC>